ArticleFunctional & integrative genomics2026
MYC-SEPT11 Axis Promotes osteoblast differentiation and bone formation via PI3K/AKT and RhoA/ROCK signaling pathways.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osteoporosis (OP), an aging-related skeletal disorder characterized by compromised bone density and deteriorated microarchitecture, presents significant challenges in understanding its molecular underpinnings. This study aims to identify novel transcriptional regulators of osteoblast differentiation and elucidate their mechanistic roles in OP pathogenesis. Through integrated analysis of single-cell and bulk RNA-seq datasets from OP patients, combined with machine-learning algorithms, SEPT11 was identified as a key downregulated gene. Functional validation was performed using human bone marrow-derived mesenchymal stem cells (BM-MSCs) induced for osteogenic differentiation. SEPT11 was overexpressed through lentiviral transduction, with osteogenic capacity assessed by ALP staining, Alizarin Red S staining, and quantification of osteogenic markers (RUNX2, OCN, ALP, PINP) and bone resorption marker TRACP-5b. Mechanistic investigations employed chromatin immunoprecipitation (ChIP)-qPCR, dual-luciferase reporter assays, and pathway inhibition studies. An ovariectomized (OVX) mouse model received intra-articular AAV9-SEPT11 for in vivo validation, with bone microarchitecture analyzed by micro-CT and bone formation markers measured. SEPT11 was significantly downregulated in OP and positively correlated with osteogenic differentiation. In BM-MSCs, SEPT11 overexpression enhanced expression of RUNX2, OCN, ALP, and PINP, decreased TRACP-5b, increased mineralization capacity, and concurrently activated both PI3K/AKT and RhoA/ROCK signaling pathways. MYC was established as a direct transcriptional activator binding to the SEPT11 promoter. MYC knockdown abolished SEPT11-mediated osteogenic promotion and pathway activation. In OVX mice, AAV9-SEPT11 administration improved bone mass, restored trabecular micro-architecture, and elevated bone formation markers. This study identifies a previously uncharacterized MYC/SEPT11 regulatory axis crucial for osteoblast differentiation. SEPT11, transcriptionally activated by MYC, promotes osteogenesis through simultaneous activation of PI3K/AKT and RhoA/ROCK pathways. These findings provide novel insights into OP pathogenesis and suggest potential therapeutic targets for postmenopausal OP.
Indexed as
Identifiers
41803291What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.